The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c.) versus intravenous (i.v.) formulation of rituximab given with chemotherapy in previously untreated patients with CD20+ diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab) / Rummel, M; Kim, T M; Aversa, F; Brugger, W; Capochiani, E; Plenteda, C; Re, F; Trask, P; Osborne, S; Smith, R; Grigg, A. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 28:4(2017), p. 836-842. [10.1093/annonc/mdw685]

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

AVERSA, Franco;
2017

Abstract

The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c.) versus intravenous (i.v.) formulation of rituximab given with chemotherapy in previously untreated patients with CD20+ diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab) / Rummel, M; Kim, T M; Aversa, F; Brugger, W; Capochiani, E; Plenteda, C; Re, F; Trask, P; Osborne, S; Smith, R; Grigg, A. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 28:4(2017), p. 836-842. [10.1093/annonc/mdw685]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2823639
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 58
social impact